Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBIT (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of EBIT data on record, last reported at -$1.0 million in Q3 2025.

  • For Q3 2025, EBIT rose 10.82% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$3.6 million, up 38.68%, while the annual FY2024 figure was -$3.6 million, 71.99% up from the prior year.
  • EBIT reached -$1.0 million in Q3 2025 per CYCN's latest filing, up from -$1.7 million in the prior quarter.
  • Across five years, EBIT topped out at $12.4 million in Q4 2022 and bottomed at -$16.2 million in Q2 2021.
  • Average EBIT over 5 years is -$5.0 million, with a median of -$1.9 million recorded in 2023.
  • Peak YoY movement for EBIT: skyrocketed 186.44% in 2022, then tumbled 114.48% in 2023.
  • A 5-year view of EBIT shows it stood at -$14.3 million in 2021, then surged by 186.44% to $12.4 million in 2022, then crashed by 114.48% to -$1.8 million in 2023, then skyrocketed by 127.97% to $502000.0 in 2024, then plummeted by 300.4% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$1.0 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.